← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Propionic acid derivatives
oxaprozin
M01AE12
Forms & Strengths
- Tablets: 600 mg
- Capsules: 600 mg
Adult Dosing
- Osteoarthritis: 1200 mg once daily or 600 mg twice daily
- Rheumatoid arthritis: 1200 mg once daily or 600 mg twice daily
- Ankylosing spondylitis: 1200 mg once daily or 600 mg twice daily
- Acute pain: 1200 mg once daily
Pediatric Dosing
- Not established for children under 16 years old
- Juvenile rheumatoid arthritis (JRA): 22-31 mg/kg/day in 2 divided doses (for children 6-16 years old)
Indications
- Treatment of osteoarthritis
- Treatment of rheumatoid arthritis
- Treatment of ankylosing spondylitis
- Treatment of acute pain
Mechanism of Action
- Inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)
- Blocks the synthesis of prostaglandins
- Reduces inflammation, pain, and fever
Contraindications
- Known hypersensitivity to oxaprozin or other NSAIDs
- Active peptic ulcer disease
- Recent gastrointestinal bleeding or perforation
- Severe renal impairment (CrCl < 30 mL/min)
- Severe hepatic impairment
Adverse Reactions
- Gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, ulcers, and bleeding
- Central nervous system: dizziness, headache, and somnolence
- Renal: renal impairment, increased serum creatinine, and hyperkalemia
- Hepatic: elevated liver enzymes and liver toxicity
- Hematologic: anemia and thrombocytopenia
Drug Interactions
- Aspirin: increased risk of gastrointestinal toxicity
- Warfarin: increased anticoagulant effect
- Lithium: increased lithium levels
- Methotrexate: increased methotrexate levels and toxicity
- Diuretics: decreased diuretic effect and increased risk of renal impairment
Curated Content: Needs Vetting Before Put to Clinical Use